Vol 7: PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.Reportar como inadecuado



 Vol 7: PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.


Vol 7: PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 7: PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
This article is from OncoTargets and therapy, volume 7.AbstractRenal cell carcinoma RCC is the most common primary malignant tumor of the kidney in adults, representing approximately 4% of all adult cancers in the United States. Metastatic RCC is poorly responsive to conventional cytotoxic chemotherapies but can be sensitive to T-cell-directed immunotherapies such as interferon-α or interleukin-2. Despite recent progress in the application of antiangiogenic -targeted therapies- for metastatic RCC, high-dose interleukin-2 remains an appropriate first-line therapy for select patients and is associated with durable complete remissions in a small fraction of treated patients. Thus, advanced RCC provides a unique opportunity to investigate the requirements for effective antitumor immunotherapy. Accumulating evidence suggests that resistance mechanisms exploited by RCC and other tumor types may play a dominant role in limiting the effectiveness of tumor-reactive adaptive immune responses. Expression of the inhibitory coreceptor programmed cell death-1 PD-1 on tumor-infiltrating lymphocytes within RCC tumors, as well as the expression of the PD-1 ligand PD-L1 on RCC tumor cells, are strong negative prognostic markers for disease-specific death in RCC patients. Monoclonal antibodies targeting either PD-1 or PD-L1 have now entered clinic trials and have demonstrated promising antitumor effects for refractory metastatic RCC. This review summarizes the results of published and reported studies of PD-1- and PD-L1-targeted therapies enrolling patients with advanced RCC, focusing on key safety, toxicity, and efficacy end points. Prospects for advanced phase clinical testing and novel therapy combinations with PD-1- and PD-L1-targeted agents are discussed.



Autor: Tykodi, Scott S

Fuente: https://archive.org/







Documentos relacionados